# Junta clínica — PT-pseudo_f80c073525b1 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_f80c073525b1",
  "pid": "PT-pseudo_f80c073525b1",
  "task": 1,
  "psa": 12.0,
  "age": 71,
  "months": 1,
  "pirads": "5",
  "psad": 0.366,
  "psav": 1.69,
  "psap": 10.4,
  "vol": 32.82,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.86149156,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 12 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 33 mL. DRE nodus. csPCa 0.86.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "65 kg",
    "height": "171 cm",
    "bmi": "22.2",
    "bp": "135/71 mmHg",
    "hr": "63 bpm",
    "smoking": "Ex-smoker (20 pack-yr, quit 2015)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent prostatic antigen elevation alongside recent multiparametric imaging review drives the current urological consultation."
    },
    {
      "s": "History",
      "t": "At 71 years of age, the retired shopkeeper first entered clinical evaluation for prostatic antigen elevation in 2022, entering a period of standard observation. Prior biopsy bucket: None. Moderate lower urinary tract complaints surface, yielding an IPSS score of 17 driven by nocturia and a diminished stream; conservative management suffices. Nuptial status is married, yet daily residence is solitary, with an adult son living in close proximity who provides regular oversight. Physical activity remains robust, featuring three weekly runs covering five kilometres each, alongside total alcohol abstinence. Tobacco use ceased in 2015 after a cumulative 20 pack-year exposure. Surgical past includes a childhood appendectomy and a 2018 right knee arthroscopy, both recovered without complication. Recent activities encompass a routine cognitive screening at a memory clinic, a declined invitation to clinical research, and a two-week Portuguese vacation completed without event. Unexplained weight reduction, skeletal discomfort, and haematuria are categorically denied. Comorbid conditions are absent. Active pharmacotherapy is nil."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: moderately enlarged gland harboring a discrete, firm nodule within the left mid-gland sector; mobility: fixed; asymmetry: notable. Abdominal and cardiovascular surveys reveal no abnormalities, characterized by clear lung fields and regular cardiac rhythms. Hemodynamic parameters remain steady. Overall appearance reflects robust wellness, corresponding to an ECOG performance status of 0."
    }
  ],
  "occupation": "retired shopkeeper",
  "marital": "Married",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Memory clinic — baseline screening"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 17/35 (moderate LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_f80c073525b1
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.366 ng/mL²
  - PSA velocity: 1.69 ng/mL/yr
  - Prior PSA: 10.4 ng/mL
  - Prostate volume: 32.82 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86149156 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 12 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 33 mL. DRE nodus. csPCa 0.86.

Vitals: weight 65 kg, height 171 cm, BMI 22.2, BP 135/71 mmHg, HR 63 bpm. Smoking: Ex-smoker (20 pack-yr, quit 2015).

Chief complaint: Persistent prostatic antigen elevation alongside recent multiparametric imaging review drives the current urological consultation.

History: At 71 years of age, the retired shopkeeper first entered clinical evaluation for prostatic antigen elevation in 2022, entering a period of standard observation. Prior biopsy bucket: None. Moderate lower urinary tract complaints surface, yielding an IPSS score of 17 driven by nocturia and a diminished stream; conservative management suffices. Nuptial status is married, yet daily residence is solitary, with an adult son living in close proximity who provides regular oversight. Physical activity remains robust, featuring three weekly runs covering five kilometres each, alongside total alcohol abstinence. Tobacco use ceased in 2015 after a cumulative 20 pack-year exposure. Surgical past includes a childhood appendectomy and a 2018 right knee arthroscopy, both recovered without complication. Recent activities encompass a routine cognitive screening at a memory clinic, a declined invitation to clinical research, and a two-week Portuguese vacation completed without event. Unexplained weight reduction, skeletal discomfort, and haematuria are categorically denied. Comorbid conditions are absent. Active pharmacotherapy is nil.

Physical examination: DRE — texture: moderately enlarged gland harboring a discrete, firm nodule within the left mid-gland sector; mobility: fixed; asymmetry: notable. Abdominal and cardiovascular surveys reveal no abnormalities, characterized by clear lung fields and regular cardiac rhythms. Hemodynamic parameters remain steady. Overall appearance reflects robust wellness, corresponding to an ECOG performance status of 0.

Patient info: retired shopkeeper; Married; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 17/35 (moderate LUTS).

Recent other appointments: Memory clinic — baseline screening.
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.85
  uncertainty  +/- 0.06 epistemic (95% band 0.74-0.97); among patients I cannot tell apart the outcome was 0.60 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 71 (2% of my signal; from age) · DRE = Nodus (10% of my signal; from dre_suspicious) · PSA = 12 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 32.82 mL (1% of my signal; from log_vol, vol) · PSA density = 0.366 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.86 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PI-RADS = 5
  important  prior biopsy = None
  noted      age = 71 · DRE = Nodus · PSA = 12 ng/mL · prostate volume = 32.82 mL · PSA density = 0.366 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: clear — the rule matched the reading urologist in 24 of 24 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.80: PI-RADS 5, PSA 15.8, PSAD 0.318, age 67, DRE Nodus -> BIOPSY (clear). He wrote: "Younger patient, no reported comorbidity, high elevated PSA, high PSAdensity, PIRADS5, positive DRE. Clear indication biopsy."
  2. distance 1.23: PI-RADS 5, PSA 7.6, PSAD 0.236, age 78, DRE Nodus -> BIOPSY (borderline). He wrote: "This is borderline. A P5 but old man and moderately PSA with no symptoms."
  3. distance 1.57: PI-RADS 5, PSA 12.0, PSAD 0.411, age 71, DRE Normal -> BIOPSY (borderline). He wrote: "P5 in 71 years old patient with no major comorbidities"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PSA = 12 ng/mL · PI-RADS = 5
  important  age = 71
  noted      prior biopsy = None · family history = not opened (0 of 91) · DRE = Nodus · prostate volume = 32.82 mL · PSA density = 0.366 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the precedents agree (1.00) and the library is right 92% of the time in this situation out of fold

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   PI-RADS = 5
  important  age = 71 · PSA = 12 ng/mL
  noted      prior biopsy = None · family history = not opened (0 of 91) · DRE = Nodus · prostate volume = 32.82 mL · PSA density = 0.366 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using the PI-RADS score to trigger a biopsy, stating, "a PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naive patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]." This requires a decision based on the PI-RADS score.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of BIOPSY p(biopsy) = 0.85 is high, but the guideline treats the PI-RADS score as the primary trigger. The guideline suggests that a PI-RADS $\ge 3$ triggers the consideration for biopsy, which is what EXPERT-COHORT confirms is the rule. The guideline suggests that the prior biopsy status is a significant predictor, and the guideline makes the prior biopsy status decisive, whereas EXPERT-STRUCTURED marked it as important. The guideline suggests that the patient's PI-RADS score is the key variable, which EXPERT-COHORT marks as decisive. The guideline suggests that the patient's csPCa probability is a factor, which EXPERT-STRUCTURED marked as noted. The guideline requires the patient's prior biopsy status to be established, which is a fact the panel does not represent.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at None the guideline suggests that a PI-RADS $\ge 3$ triggers the consideration for biopsy, which means the decision hinges on the PI-RADS score.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline does not explicitly state what the PSA trend means in this context, but the panel shows a PSA velocity of 1.69 ng/mL/yr.
laboratory_results - the laboratory results: the guideline links PSA density to risk stratification, suggesting that a PSA density of 0.366 ng/mL/cc is a factor in risk assessment.
family-history anamnesis - the family history of prostate cancer: the guideline suggests that the family history is a factor in risk assessment, which is a variable the conference still needs to establish.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on whether the PI-RADS 5 score, as confirmed by the cohort, is sufficient to trigger a biopsy, given the guideline's focus on this score and the lack of prior biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What does the PSA velocity of 1.69 ng/mL/yr signify in the context of the guideline?
  previous_notes (get_previous_notes) -> What is the prior biopsy status and surveillance plan?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the prior biopsy status as per previous_notes?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "What should be done given the PI-RADS = 5?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI Prostate | Date: 15 Jan 2025 | Facility: Amsterdam UMC (VUmc)
COMPARISON: new
LESION: PI-RADS 5 lesion in the left mid-gland peripheral zone.

psa_trend
The PSA velocity of 1.69 ng/mL/yr signifies a rising trend in PSA levels over time.

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: None
SURVEILLANCE: Interim observation proceeds.
TREATMENT: conservative management suffices.

WHAT I DID NOT OPEN
laboratory_results, family-history anamnesis, pathology report.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS = 5 (from EXPERT-COHORT and EXPERT-LIBRARY)
PSA velocity of 1.69 ng/mL/yr (from psa_trend)
Prior biopsy = None (from EXPERT-STRUCTURED and EXPERT-COHORT)

AGAINST sampling this patient now
nothing

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 12.00 ng/mL over 3 points spanning 34 months; velocity +2.93 ng/mL per year; doubling time about 20 months.
PROJECTION at 6 months: 19.9 ng/mL, conformal 95% band 5.7-69.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 12 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.82
  uncertainty  +/- 0.06 epistemic (95% band 0.70-0.94), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = None (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 12 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 32.82 mL (4% of my signal; from log_vol, vol) · PSA density = 0.366 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: clear — 'firm' tier; out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.85  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.82  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           None                         E1:DEC E3:DEC cohort:IMP library:not E2:—            -> noted
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          71                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Nodus                        E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          12 ng/mL                     E1:not E3:not cohort:not library:DEC E2:not          -> important
  vol          32.82 mL                     E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.366                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.86                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:DEC library:DEC E2:—            -> decisive
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) answered the moderator's question Q1. The previous_notes explicitly state "BIOPSY SESSIONS: None," which answers the prior biopsy status.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY. The registrar's report confirmed PI-RADS = 5, which triggered the cohort criterion, leading to the PANEL ANSWER of BIOPSY.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the prior biopsy status as per previous_notes? This was answered by the registrar, who reported "BIOPSY SESSIONS: None."

WHAT CARRIES WEIGHT, AND WHY
<pirads>: decisive: 5 (from EXPERT-COHORT and EXPERT-LIBRARY) This is decisive because the cohort criterion, which is the rule that fired, is based on PI-RADS $\ge 3$. I agree with the PANEL-PROTOCOL's marking of this as decisive.
<prior biopsy>: decisive: None (from EXPERT-STRUCTURED and EXPERT-COHORT) This is decisive because the cohort criterion is explicitly defined by the prior biopsy status. I agree with the PANEL-PROTOCOL's marking of this as decisive.
<psa>: important: 12 ng/mL (from EXPERT-STRUCTURED) This is important as it was noted by multiple experts, supporting the overall high-risk assessment. I agree with the PANEL-PROTOCOL's marking of this as important.
My confidence in the record as it stands is clear.

MY SUGGESTION TO THE CHAIR
The record is in a state to be decided based on the guideline's focus on the PI-RADS score. The panel protocol's answer rests entirely on the retrieved finding that the PI-RADS score was 5, which is confirmed by the cohort criterion.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

71 y/o, PSA 12.0, PI-RADS 5, biopsy-naive. PI-RADS 5 mandates sampling, supported by high PSA density of 0.366. No prior pathology to contraindicate sampling.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
